Skip to Main Content

Paper Details

Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
1
2023
AKT1, Erdafitinib, FGFR, FGFR2, FGFR2 fusion, FGFR2/3, FGFR3, TP53, TP53 mutations, cell, cell-free (cf) DNA, cfDNA, erdafitinib, metastatic, metastatic urothelial cancer, patient, patients, primary, second, tumor, tumors, urothelial carcinoma
Author NameAffiliation
Michael F BergerMemorial Sloan Kettering Cancer Center
  • 1 - 1

Datasets

Release 1.2